esketamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4468 33643-46-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • spravato
  • esketamine HCl
  • esketamine hydrochloride
  • esketamine
  • l-Ketamine
  • Molecular weight: 237.73
  • Formula: C13H16ClNO
  • CLOGP: 2.93
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 29.10
  • ALOGS: -3.71
  • ROTB: 2
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
8 mg N

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 18, 2019 EMA Janssen-Cilag International N.V.
May 3, 2019 FDA JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dissociation 1119.73 39.60 170 1821 2121 50601012
Sedation 327.83 39.60 96 1895 30514 50572619
Suicidal ideation 275.67 39.60 97 1894 55288 50547845
Suicide attempt 112.69 39.60 50 1941 51682 50551451
Anxiety 85.56 39.60 64 1927 177542 50425591
Dissociative disorder 67.41 39.60 11 1980 214 50602919
Blood pressure increased 46.86 39.60 40 1951 133092 50470041
Device malfunction 40.66 39.60 17 1974 15104 50588029
Panic attack 39.78 39.60 18 1973 19324 50583809

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dissociation 438.47 63.89 66 796 1063 29572602
Suicidal ideation 163.45 63.89 54 808 34662 29539003
Sedation 158.52 63.89 45 817 17360 29556305
Drug ineffective 82.91 63.89 74 788 363096 29210569

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dissociation 1108.90 45.73 170 1885 2841 64493836
Sedation 416.79 45.73 118 1937 41344 64455333
Suicidal ideation 321.41 45.73 108 1947 66434 64430243
Suicide attempt 146.41 45.73 62 1993 70945 64425732
Anxiety 90.07 45.73 64 1991 202585 64294092
Dissociative disorder 76.45 45.73 13 2042 408 64496269
Blood pressure increased 59.77 45.73 47 2008 172505 64324172
Drug ineffective 49.40 45.73 92 1963 840155 63656522
Device malfunction 48.54 45.73 19 2036 17614 64479063
Dizziness 47.40 45.73 63 1992 430100 64066577

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01AX14 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Other general anesthetics
ATC N06AX27 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
MeSH PA D000928 Antidepressive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
CHEBI has role CHEBI:38877 intravenous anesthetics
CHEBI has role CHEBI:60643 N-methyl-D-aspartate receptor antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Depressive disorder indication 35489007
Arteriovenous malformation contraindication 24551003
Aneurysm contraindication 432119003 DOID:178




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.65 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL 9592207 March 20, 2027 TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL 8785500 March 5, 2033 TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL 10869844 Sept. 10, 2035 TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84 MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL 10869844 Sept. 10, 2035 TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84 MG WEEKLY OR 1X EVERY TWO WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL 10869844 Sept. 10, 2035 TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE IN CONJUNCTION WITH AN ORAL ANTIDEPRESSENT
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL 11311500 Sept. 10, 2035 TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84 MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL 11311500 Sept. 10, 2035 TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84 MG WEEKLY OR 1X EVERY TWO WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL 11311500 Sept. 10, 2035 TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE IN CONJUNCTION WITH AN ORAL ANTIDEPRESSENT
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL 11173134 Sept. 14, 2035 TREATMENT OF TRD IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR 1X EVERY TWO WEEKS TO ADULTS WHO HAVE BEEN ADMINISTERED ESKETAMINE IN A INDUCTION PHASE FOR ABOUT 4 WEEKS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL July 31, 2023 TREATMENT OF SYMPTOMS IN ADULTS WITH MAJOR DEPRESSIVE DISORDER (MDD) WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR.
EQ 28MG BASE SPRAVATO JANSSEN PHARMS N211243 March 5, 2019 RX SPRAY NASAL March 5, 2024 NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glutamate NMDA receptor Ion channel ANTAGONIST Ki 6.16 SCIENTIFIC LITERATURE

External reference:

IDSource
D07283 KEGG_DRUG
33643-47-9 SECONDARY_CAS_RN
4038229 VANDF
4038230 VANDF
CHEBI:60799 CHEBI
CHEMBL395091 ChEMBL_ID
CHEMBL2364609 ChEMBL_ID
DB11823 DRUGBANK_ID
C000629870 MESH_SUPPLEMENTAL_RECORD_UI
9152 IUPHAR_LIGAND_ID
7884 INN_ID
50LFG02TXD UNII
182137 PUBCHEM_CID
2119365 RXNORM
309966 MMSL
36280 MMSL
d09174 MMSL
015448 NDDF
015449 NDDF
785816006 SNOMEDCT_US
789486001 SNOMEDCT_US
C2825616 UMLSCUI
JC9 PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Spravato HUMAN PRESCRIPTION DRUG LABEL 1 49396-0280 SPRAY 28 mg NASAL Export only 1 sections
Spravato HUMAN PRESCRIPTION DRUG LABEL 1 50458-028 SOLUTION 28 mg NASAL NDA 38 sections